Recent Updates — SNNUF

Smith & Nephew plc announced the redemption of its entire outstanding $350 million principal amount of 5.150% Notes due 2027. The securities will be redeemed on October 5, 2026, at a price of 100.245%, equating to $1,002.45 per $1,000 principal amount, plus accrued interest of $2.15 per $1,000 for a total payment of $1,004.60 per bond. This action extinguishes the company's debt obligation under the Indenture dated October 14, 2020. Smith & Nephew plc operates in the medical technology industry, designing and manufacturing orthopaedic, sports medicine, and wound management products.

Smith & Nephew plc filed this report to incorporate documents into its Form F-3 Registration Statement regarding the issuance of $700,000,000 aggregate principal amount of 5.750% Notes due 2036. The filing includes a First Supplemental Indenture dated September 11, 2026, and legal opinions from Davis Polk & Wardwell London LLP. This debt issuance represents a significant financing activity for the company. Smith & Nephew plc operates in the medical technology industry, manufacturing orthopaedic, sports medicine, and ENT products.

Smith+Nephew announced a cash tender offer on September 8, 2026, to purchase up to $250 million of its outstanding 2.032% Senior Notes due 2030 from registered holders. The company intends to use proceeds from a concurrent offering of new senior notes due 2036 to fund the repurchase, aiming to proactively manage its debt portfolio and extend the average maturity profile. The tender offer is conditional upon receiving sufficient gross proceeds from the new issuance. Pricing will be determined on September 15, 2026, with settlement expected by September 18, 2026. Smith+Nephew operates in the medical technology industry, manufacturing devices for orthopaedics, sports medicine, and wound management.